Development of laboratory models to study Breast Cancer Deborah Holliday Breast Research Group Section of Pathology & Tumour Biology Section of Pathology.

Slides:



Advertisements
Similar presentations
Major Cancer Milestones
Advertisements

Progress Against Breast Cancer
TOP2A IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN UNSELECTED BREAST CANCER Amit Pancholi Molecular Profiling of Breast Cancer: Predictive Markers of Long.
Mammary ductal carcinoma
Neoplasia 1: Introduction. terminology oncology: the study of tumors neoplasia: new growth (indicates autonomy with a loss of response to growth controls)
Slide Seminar Sami Shousha, MD, FRCPath Department of Histopathology, Charing Cross Hospital & Imperial College, London Amman, November 2013.
First HAYAT Annual Patients Forum – 21 st March 2010 – SAS, Kuwait First HAYAT Annual Patients Forum 21 st March 2010 Al Hashimi II Ballroom – SAS Hotel.
PLWC Slide Deck Series: Understanding Breast Cancer
Pathology Journal Reading
PCR Application: Can Breast Cancer be Cured?. Normal, Healthy Cells Cells can change or differentiate to become specialised according to the tissue that.
What is cancer? A cancer is a malignant tumor, which are cells that multiply out of control, destroying healthy tissues (Dictionary)
Breast Cancer 101 Barbara Lee Bass, MD, FACS Professor of Surgery
Breast Cancer By Kajal Haghmoradi.
Genomics Lecture 7 By Ms. Shumaila Azam. Tumor Tumor – abnormal proliferation of cells that results from uncontrolled, abnormal cell division A tumor.
By Rachel, Xiao Xia, Helen. Introduction Definition Symptoms Causes Prevention Treatment Prognosis Statistics Conclusion.
Pathology, & Treatments.  Lymphadenitis  Lymphadenopathy  Persistent generalized lymphadenopathy  Lymphangiogram.
Cancer Card Game Answers etc.
  Surgery  Hormone Therapy  Radiation  Chemotherapy  Immunotherapy  Targeted therapy Methods of Treatment
Ductal Carcinoma in situ
Breast Cancer By George Rezk.
White blood cells & the immune system What does it mean to be immune to something? Leucocyte (WBC) Phagocytes (engulf & destroy) = Inflammation Lymphocytes.
Breast Cancer Clinical Cases Daniel A. Nikcevich, MD, PhD SMDC Cancer Center April 20, 2009.
BREAST CANCER GROUP 6 :  Nuraini Ikqtiarzune Haryono( )  Tri Wahyu Ningsih ( )  Rani Yuswandaru ( )  Anita Rheza Fitriana Putri( )
Metastasis Steps to metastases:
 Determining the Nature of a Breast Abnormality  It is a procedure that may be used to determine whether a lump is a cyst (sac containing fluid) or a.
Prepared by: Hai Lam Lynn Yu Racheal Richie Trina Jones.
Tutorial on Breast Pathology Part I: Ductal and Lobular Neoplasias Thomas J Lawton MD, Director Seattle Breast Pathology Consultants, LLC Seattle, WA.
Breast Cancer and the Environment Taylor Dungjen Beth Rudolph.
Breast Cancer Awareness Marissa Gregg. What is Breast Cancer?  Breast Cancer forms in the breast  It is a tumor in the breast  Breast cancer is the.
 Identify different options of cancer therapy.  Most cancers are treated with a combination of approaches.
Breast Cancer. What is this Disease? Second leading cause of cancer death in women Malignant (cancerous) tumor –Develops from cells in the breast that.
 General recommendations -adjuvant systemic therapy :with tamoxifen or multiple-chemotherapy agent :lower the incidence of recurrence by about 30% - in.
Companion PowerPoint slide set Obesity-associated breast cancer risk: a role for epigenetics? This teacher slide set was created by Dana Haine, MS, of.
Ductal Carcinoma In Situ Shahla Masood, M.D. Professor of Pathology University of Florida College of Medicine - Jacksonville Chief of Pathology and Laboratory.
Breast disease MUDr. Petr Šafář, CSc.. Anatomy of female breast.
Katie Ludwig FY1.   50, 285 New cases of breast cancer  11, 716 deaths  78% - 10 year survival rates  27% preventable cases  Source:
Objectives Discuss the history of breast cancer. Describe the pathology of breast cancer and list significant tumor markers. Differentiate IHC testing.
Breast Cancer By: Christen Scott.
By: Ashley Rodriguez, Yara parada, Briana Mendoza, Jackie Hernandez
Training Module 3 – Version 1.1 For Internal Use Only ® Radiation Therapy 
Breast Cancer. Introduction  As old as 1600 BC  Emerges from inner lining of milk ducts  Or the lobules that supply milk  Types:  DCIS  LCIS.
 Among all cancers, breast cancer has been the 2 nd leading cause of death in women (right behind lung cancer)  Causes about 40,000 deaths annually.
DL Wickerham MD Deputy Chairman NRG Oncology Oct 5, 2015
Prognostic and Predictive Factors: Current Evidence for Individualized Therapy Predictive Molecular Markers: Hormone Receptor Status Presented by Kathleen.
Breast Cancer. Breast cancer is a disease in which malignant cells form in the tissues of the breast – “National Breast Cancer Foundation” The American.
Pathology.
A RAY OF HOPE: TAMOXIFEN POWERPOINT PRESENTATION BY NEIL RAKHOLIA
Marc Cote BME 181 Section 2 3/25/13 ARTIFICIAL SKIN.
Breast Cancer 1. Leukemia & Lymphoma New diagnoses each year in the US: 112, 610 Adults 5,720 Children 43,340 died of leukemia or lymphoma in
By: Anthony, Sophia, Jessica, Terrance, and Sierra.
Jacob J. Adler.  The following slides are meant for students to navigate on their own or in small groups.  They are expected to have time to research.
Treatment for Cancer. Surgery Treatment and prognosis depend on severity and spread of the cancer Treatment and prognosis depend on severity and spread.
OVERVIEW OF BREAST PATHOLOGY Shahin Sayed, MMed, FCPath(ECSA) Assistant Professor, Department of Pathology, Aga Khan University Hospital, Nairobi.
Companion PowerPoint slide set Obesity-associated breast cancer risk: a role for epigenetics? This teacher slide set was created by Dana Haine, MS, of.
La nuova biologia.blu Anatomia e fisiologia dei viventi S
Case 3 Jane McNicholas Consultant Oncoplastic Breast Surgeon
Multistep model of breast cancer progression
Sonography of the Breast Part III
Mesenchymal Stem Cells and Breast Cancer
BREAST CANCER A full classification includes histopathological type, grade, stage (TNM), receptor status, and the presence or absence of genes as determined.
Marcelo Calil Instituto Brasileiro de Controle do Câncer
Thanh Nhan Hospital MALE BREAST CANCER: CASE REPORT
Homeostasis in the breast
Handling and Evaluation of Breast Cancer Biopsy
Breast Cancer.
C11 Breast cancer Treatments
Prof Matt Smalley, Director
EXPRESSION OF PD-L1 IN TRIPLE NEGATIVE BREAST CANCER (SP142) AND IMPLEMENTATION OF VENTANA HER2 Dual ISH DNA ASSAY Alexander Makanga Senior Biomedical.
(Handling and Evaluation of Breast Cancer Biopsy)
Presentation transcript:

Development of laboratory models to study Breast Cancer Deborah Holliday Breast Research Group Section of Pathology & Tumour Biology Section of Pathology and Tumour Biology

Outline  Introduction to the cells found in breast tissue  Changes in breast cells during breast cancer  Designing a model of breast cancer  methods  Use of the model: A tool for looking at cancer progression

Cellular components of the normal breast  Luminal epithelial cells:  Milk producing cells  Hormone responsive ER-alpha positive cells  Myoepithelial cells:  Surround the luminal cells  Contractile cells  Luminal and Myoepithelial cells form the glandular unit of the breast  Fibroblasts:  Form the structural component of the surrounding breast tissue  Produce proteins important for maintaining breast structure  Other cell types  Blood vessels, fat cells, inflammatory cells

Fibroblasts Myoepithelial cells Tumour cells Luminal cells Normal breast tissue  Cells look ordered in appearance Pre-invasive breast cancer  Tumour cells in the centre start to grow out of control Invasive breast cancer  Tumour cells escape into the surrounding breast tissue  Ordered structure of the tissue is lost Breast Cancer Progression

Pre-invasive breast cancer: Ductal carcinoma in situ (DCIS)  DCIS is characterised by confinement of tumour cells to the breast glandular unit  DCIS accounts for 40% of screen detected breast carcinoma  25-30% of untreated DCIS will progress to invasive carcinoma

Problems with treatment of DCIS Mastectomy Patient is cured but ? Overtreatment ? Conservative surgery A proportion of tumours will recur Some of those will progress to invasive carcinoma Important to define which DCIS cases are likely to progress A better understanding of the biology of tumour invasion may reveal new targets for therapies

Designing a human model of breast cancer  The model would need to include 3 major cell types involved in breast cancer:  Tumour cells.  Myoepithelial cells (protector cells).  Fibroblasts (tumour helper cells).  Cells would need to be grown in culture conditions which resemble those in the body:  Able to grow in 3 dimensions rather than on a plastic Petri dish.  Such a model would be a valuable tool:  To help us understand how breast cancer progresses.  To allow us to test new drugs for therapy.  To potentially identify new targets for future drug development.

Methods  We isolated cells from normal breast tissue or from breast cancer tissue and grew then in a 3 dimensional matrix of collagen.  By labelling our cells with different colours we were able to identify the different cell types in our model.  We used the model to investigate whether fibroblasts are able to make pre-invasive lesions become invasive.

Results F B Day 1Day 3Day 5Day 7 Blue: Tumour cells Red: Myoepithelial cells Green: Normal Fibroblasts Green: Tumour Fibroblasts Ductal carcinoma in situ (DCIS) Invasive breast Carcinoma

Quantifying the model lum/myo/Nfib mcf/myo/TAF number of structures per field * Normal Fibroblasts Tumour Fibroblasts Normal Fibroblasts Tumour Fibroblasts

How we are using the model Different tumour cells to represent different types of breast cancer Different fibroblasts to understand why in some patients cancer progresses faster than in others Include drugs into the model with tumour fibroblasts to see if we can prevent ‘invasion’ –Established drugs –New Drugs = pre-clinical drug screen We have a model which we can use to study the biology of breast cancer This will help us understand how breast cancer progresses Summary

Using 3D models to study radio- resistance in Breast Cancer Laura Smith Breast Research Group Section of Pathology & Tumour Biology Section of Pathology and Tumour Biology

Outline  Radiotherapy  Issues with radiotherapy  What would help overcome these issues?  The use of 3D models

Radiotherapy  Reduces risk of the cancer coming back  Is given to many breast cancer patients  All patients having breast conserving surgery  Patients having a mastectomy but at high risk of the cancer coming back

Issues with Radiotherapy  Unpleasant side effects  Short term  Long term  Stressful regime  Daily hospital visits 5 days/ week for 3 weeks  Limited availability of treatment machines  Long waiting lists in some areas  Not all patients will benefit  Some patients cancer will come back anyway

Overcoming these issues  Better patient selection  Estrogen Receptor for Tamoxifen therapy  HER2 for Herceptin therapy  Nothing analogous to guide radiotherapy  Why do some cancers respond well to radiotherapy whilst others do not?  What factors are involved?  Radio-sensitizing drugs?

Our Study  It is not only cancer cells that are exposed to radiotherapy but also the fibroblasts  Do fibroblasts influence breast cancer cell response to radiotherapy?  Do fibroblasts differentially influence the response of different breast cancer types?

Use of 3D Models

Summary  Reduce side effects and improve quality of life for patients that will not benefit  Allow drs to select another type of treatment that will work for these patients  Reduce waiting times for those patients that will benefit thereby increasing survival